[Dysimmune neuropathies: current diagnosis and therapy].
Dysimmune neuropathies encompass an acute form, Guillain-Barré syndrome (GBS), and mainly 3 chronic forms: chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), multifocal motor neuropathy, and polyneuropathy associated with anti-MAG (myelin-associated-glycoprotein) IgM monoclonal gammopathy. Recent concepts have concerned both incidence and mortality rates, and better scoring system for predict outcome in GBS, but new therapeutical strategy is needed for the so-called "benign" forms and for relapsing forms after first-line IVIg therapy. In chronic forms, criteria for diagnosis and guidelines for management have been edited in the recent years, together with recommendations for outcome measures. However, there is still a need for knowing the better outcome measures, and to elaborate new trials, mainly focusing on the long-term management of the patients.
Léger
Jean-Marc
JM
Centre de référence maladies neuromusculaires rares Paris-Est, France. jean-marc.leger@psl.aphp.fr
Larue
Sandrine
S
Dashi
Florian
F
D020275:Guillain-Barre Syndrome / Q000175:diagnosis / Q000628:therapy; D006801:Humans; D007075:Immunoglobulin M / Q000276:immunology; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D008998:Monoclonal Gammopathy of Undetermined Significance / Q000276:immunology / Q000628:therapy; D016472:Motor Neuron Disease / Q000276:immunology / Q000628:therapy; D018992:Myelin-Associated Glycoprotein / Q000276:immunology; D011115:Polyneuropathies / Q000276:immunology / Q000628:therapy; D011129:Polyradiculoneuropathy / Q000175:diagnosis* / Q000628:therapy
D007075:Immunoglobulin M; D016756:Immunoglobulins, Intravenous; D018992:Myelin-Associated Glycoprotein